产品说明书

Fosfomycin Disodium Salt

Print
Chemical Structure| 26016-99-9 同义名 : 磷霉素钠 ;MK-0955 sodium;Fosfomycin sodium;Phosphonomycin disodium salt;MK 955;Forocyle S;Disodium phosphonomycin;Disodium fosfomycin;Phosphonemycin Disodium;Fosfomycin Disodium
CAS号 : 26016-99-9
货号 : A784892
分子式 : C3H5Na2O4P
纯度 : ≥700IU/mg
分子量 : 182.023
MDL号 : MFCD00056853
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 120 mg/mL(659.26 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Fosfomycin (disodium salt) is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin has a synergistic effect when used in combination with other antimicrobial agents that act via a different mechanism of action, thereby allowing for reduced dosages and lower toxicity[3]. Oral fosfomycin is mainly used in the treatment of urinary tract infections, particularly those caused by Escherichia coli and Enterococcus faecalis. Intravenous fosfomycin has been administered in combination with other antibiotics for the treatment of nosocomial infections due to multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria. Fosfomycin is well tolerated, with a low incidence of adverse events[4]. Fosfomycin is the treatment of choice for cystitis in immunocompetent patients, patients with transplants, pregnant women and in pediatric settings. The drug is especially useful due to its microbiological activity and oral posology in cystitis caused by ESBL bacteria. Administer intravenously at high doses and combined with other antimicrobial agents, Fosfomycin has also been shown active in combination with daptomycin or imipenem in osteoarticular infections by methicillin-resistant Staphylococcus aureus[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02178254 Pseudomonas Infection Phase 1 Completed - United States, Kansas ... 展开 >> Quintiles Phase I Services - Overland Park Overland Park, Kansas, United States, 66211-1553 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

5.49mL

1.10mL

0.55mL

27.47mL

5.49mL

2.75mL

54.94mL

10.99mL

5.49mL
参考文献

[1]Goto M, Sugiyama M, et al. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob Agents Chemother. 1981 Sep;20(3):393-7.

[2]Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2014 Aug;34(8):845-57.

[3]Dijkmans AC, Zacarías NVO, Burggraaf J, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017;6(4):24. Published 2017 Oct 31

[4]Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-e739

[5]Candel FJ, Matesanz David M, Barberán J. New perspectives for reassessing fosfomycin: applicability in current clinical practice. Rev Esp Quimioter. 2019;32 Suppl 1(Suppl 1):1-7